Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr

Pharmaceutical company Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr of 2011 compared to Rs 308 cr in a yr ago period.

Income are seen rising 8percent to Rs 2,091 cr compared to Rs 1,935 cr while the similar period.

EBITDA is likely to bounce 28percent to Rs 177 cr in July-September qtr of 2011 compared to Rs 139 cr in the similar qtr of last financial.

Operating_profit margin is anticipated to be at 8.5percent compared to 7percent yoy.

Be Sociable, Share!
Tags:

Stock Market Basics For Beginners

What Are The Securities Anyone Can Invest In?

What Are The Securities Anyone Can Invest In? * Stocks * Derivative products * Government Securities * Units of MF (Mutual Funds) for example., are a few of the stock investors in the securities market can ...…

What is Listing Agreement?

What is Listing Agreement? During the time of listing securities of a firm on a stock exchange (NSE,BSE), the firm is needed to enter into a listing deal with ...…

No Risk Mutual Fund

No Risk Mutual Fund Plenty of monetary advice written on the web thinks that the viewer is actually very logical, the stock market is very rational, and almost everything ...…

Why Do Companies Split Their Stock? Stock Split Good?

Why Do Companies Split Their Stock? Stock Split Good? [ad name="468x15- 5 link"] A company splits their stock because administration has a theoretical ideal price range for the firm’s stock. If the market price of ...…

Invest Regularly

Invest Regularly Invest Regularly : Improve the practice of adding to your recurring deposit and SIP (systematic investment plan of mutual fund) / deferred annuity ...…

Indian Share Tips

NSE Investment Site

Market Update

Share Guide

Designed by VMV
web
analytics